Key facts
- This page summarizes Matthew Gline's Form 4 filing for Roivant Sciences Ltd. (ROIV).
- 12 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 17 Dec 2025, 21:00.
Matthew Gline - 15 Dec 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)
- Reporting relationship
- CEO, Director
- Issuer ticker
- ROIV
- Reported as of
- 15 Dec 2025
- Net transaction value
- -$36,853,839
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2025, 21:00:09 UTC
- Prior SEC filing
- 18 Sep 2025
- Next SEC filing
- 01 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Gline filed Form 4 for Roivant Sciences Ltd. (ROIV) on 17 Dec 2025.
Change
- Previous filing in this sequence was filed on 18 Sep 2025.
- Current net transaction value: -$36,853,839.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001750094
Primary reporting owner
Gline Matthew
- Relationship
- CEO, Director
- Address
- C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
- Signature
- By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
- Signature date
- 17 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $950,430
- Shares
- +234,096
- Change %
- +1.4%
- Price
- $4.06
- Shares after
- 17,521,177
- Date
- 15 Dec 2025
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $4,994,140
- Shares
- -230,357
- Change %
- -1.3%
- Price
- $21.68
- Shares after
- 17,290,820
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
ROIV
transaction
Common Shares
Other
- Transaction value
- $81,062
- Shares
- -3,739
- Change %
- -0.02%
- Price
- $21.68
- Shares after
- 17,287,081
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $17,291,855
- Shares
- +1,363,711
- Change %
- +7.9%
- Price
- $12.68
- Shares after
- 18,650,792
- Date
- 15 Dec 2025
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $12,273,395
- Shares
- -566,116
- Change %
- -3%
- Price
- $21.68
- Shares after
- 18,084,676
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
ROIV
transaction
Common Shares
Other
- Transaction value
- $17,291,860
- Shares
- -797,595
- Change %
- -4.4%
- Price
- $21.68
- Shares after
- 17,287,081
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $28,819,763
- Shares
- +2,272,852
- Change %
- +13%
- Price
- $12.68
- Shares after
- 19,559,933
- Date
- 15 Dec 2025
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $20,455,665
- Shares
- -943,527
- Change %
- -4.8%
- Price
- $21.68
- Shares after
- 18,616,406
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
ROIV
transaction
Common Shares
Other
- Transaction value
- $28,819,766
- Shares
- -1,329,325
- Change %
- -7.1%
- Price
- $21.68
- Shares after
- 17,287,081
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -234,096
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 15 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 234,096
- Exercise price
- $4.06
- Footnotes
- F3
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,363,711
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 15 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,363,711
- Exercise price
- $12.68
- Footnotes
- F3
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,272,852
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 15 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,272,852
- Exercise price
- $12.68
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934.
Footnote F2
Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
Footnote F3
Award of stock options to purchase Common Shares that is fully vested.